{"id":2226,"date":"2020-06-18T08:57:09","date_gmt":"2020-06-18T06:57:09","guid":{"rendered":"https:\/\/cendoc.h12o.es\/blog\/?p=2226"},"modified":"2020-06-18T08:57:09","modified_gmt":"2020-06-18T06:57:09","slug":"enfermedades-reumaticas-covid-19-y-h12o","status":"publish","type":"post","link":"https:\/\/cendoc.h12o.es\/blog\/2020\/06\/18\/enfermedades-reumaticas-covid-19-y-h12o\/","title":{"rendered":"Enfermedades reum\u00e1ticas, COVID-19 y H12O"},"content":{"rendered":"<p>Jos\u00e9 Luis Pablos, jefe de servicio de Reumatolog\u00eda del Hospital 12 de Octubre, es el primer autor de un estudio sobre pacientes con enfermedades reum\u00e1ticas (AI\/IMID) y los riesgos frente a la COVID-19, publicado en la revista <em>Annals of Rheumatic Diseases<\/em>.<\/p>\n<p style=\"text-align: right;\"><img loading=\"lazy\" decoding=\"async\" class=\"  wp-image-3871 alignright\" src=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=216&amp;h=144\" sizes=\"(max-width: 216px) 100vw, 216px\" srcset=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=216&amp;h=144 216w, https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=150&amp;h=100 150w, https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg 275w\" alt=\"logo12\" width=\"216\" height=\"144\" data-attachment-id=\"3871\" data-permalink=\"https:\/\/coronavirusbiblioh12o.wordpress.com\/2020\/05\/06\/7-mas-del-h12o\/logo12\/\" data-orig-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg\" data-orig-size=\"275,183\" data-comments-opened=\"1\" data-image-meta=\"{&quot;aperture&quot;:&quot;0&quot;,&quot;credit&quot;:&quot;&quot;,&quot;camera&quot;:&quot;&quot;,&quot;caption&quot;:&quot;&quot;,&quot;created_timestamp&quot;:&quot;0&quot;,&quot;copyright&quot;:&quot;&quot;,&quot;focal_length&quot;:&quot;0&quot;,&quot;iso&quot;:&quot;0&quot;,&quot;shutter_speed&quot;:&quot;0&quot;,&quot;title&quot;:&quot;&quot;,&quot;orientation&quot;:&quot;0&quot;}\" data-image-title=\"logo12\" data-image-description=\"\" data-medium-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" data-large-file=\"https:\/\/coronavirusbiblioh12o.files.wordpress.com\/2020\/05\/logo12.jpg?w=275\" \/><\/p>\n<p>\u201c<a href=\"https:\/\/ard.bmj.com\/content\/annrheumdis\/early\/2020\/06\/12\/annrheumdis-2020-217763.full.pdf\" target=\"_blank\" rel=\"noopener\">Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases<\/a>\u201d es el t\u00edtulo del trabajo, firmado en colaboraci\u00f3n con Mar\u00eda Galindo y Miriam Retuerto, entre otros investigadores, en el que se recogen datos de pacientes reumatol\u00f3gicos con PCR positiva de siete hospitales espa\u00f1oles. Se parte de la falta de evidencia de los beneficios y riesgos de las terapias inmunosupresoras en pacientes con enfermedades reum\u00e1ticas frente a la COVID-19. Seg\u00fan este estudio, los pacientes con enfermedades inflamatorias cr\u00f3nicas o autoinmunidad sist\u00e9mica presentaron mayor prevalencia que los pacientes con artritis o lupus. Y se concluyte que los pacientes con enfermedades autoinmunes sist\u00e9micas (AI) o con enfermedades inflamatorias inmunomediadas (IMID) muestran un riesgo variable de COVID-19 que, al margen de la edad, puede estar influido por los tratamientos y las caracter\u00edsticas espec\u00edficas de la enfermedad.<\/p>\n<p><em>Equipo Biblioteca H12O<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jos\u00e9 Luis Pablos, jefe de servicio de Reumatolog\u00eda del Hospital 12 de Octubre, es el primer autor de un estudio sobre pacientes con enfermedades reum\u00e1ticas (AI\/IMID) y los riesgos frente a la COVID-19, publicado en la revista Annals of Rheumatic Diseases. \u201cPrevalence of hospital PCR-confirmed COVID-19 cases in patients with \u2026<\/p>\n<p class=\"continue-reading-button\"> <a class=\"continue-reading-link\" href=\"https:\/\/cendoc.h12o.es\/blog\/2020\/06\/18\/enfermedades-reumaticas-covid-19-y-h12o\/\">Continuar leyendo<i class=\"crycon-right-dir\"><\/i><\/a><\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","enabled":false},"version":2}},"categories":[4,64,46],"tags":[14,65,47],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_shortlink":"https:\/\/wp.me\/p3G9TJ-zU","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2226"}],"collection":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/comments?post=2226"}],"version-history":[{"count":1,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2226\/revisions"}],"predecessor-version":[{"id":2227,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/posts\/2226\/revisions\/2227"}],"wp:attachment":[{"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/media?parent=2226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/categories?post=2226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cendoc.h12o.es\/blog\/wp-json\/wp\/v2\/tags?post=2226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}